J&J to buy breast implant maker Mentor for $1.07B
By Linda A. Johnson, AP Business Writer
Analysts said J&J is paying "a giant premium" for the maker of MemoryGel breast implants, liposuction equipment and "barrier" skin repair products, with an eye to their long-term value for an aging population.
Under the deal, J&J will start a cash tender offer for $31 per share -- nearly double Mentor's Friday closing price of $16.15 -- for a total of $1.07 billion. J&J will assume Mentor's net debt, about $50 million, and make company a stand-alone unit in its Ethicon Inc. business, a top provider of sutures, mesh and other surgical products.
"For Mentor, what a payday!" said Erik Gordon, associate dean and head of biomedical industry programs at Stevens Institute of Technology.
Mentor shares jumped $14.43, or 89 percent, to $30.58; J&J shares, weighed down by a big decline in the broader market, fell $3.25, or 5.6 percent, to $55.33.
"It's a good space for J&J to get bigger in because it's a space with the least cost-control pricing pressures," as patients, rather than insurers or government health programs, generally pay for cosmetic surgery, Gordon said.
Johnson & Johnson doesn't have a cosmetic surgery franchise per se, but this summer it launched a collagen-based skin filler called Evolence. Some products made by Ethicon and by Ethicon Endo Surgery, which makes devices for stomach-reduction and other operations, increasingly are being used in plastic surgery, including sutures, mesh implants for facelifts, and harmonic scalpels, J&J spokesman Bill Price said.
"Mentor's going to become sort of a cornerstone for ... our strategy to become a major player in this area," he said.
Santa Barbara, Calif.-based Mentor has about 1,300 employees and had $373 million in 2007 sales.
"The addition of Mentor, a market-leader and one of the most respected companies in the aesthetic space, expands our capacity to provide physicians with products that can restore patients' appearance, self-esteem and quality of life," Alex Gorsky, the J&J company group chairman overseeing Ethicon, said in a statement.
The deal is expected to shave 3 to 5 cents per share off of J&J's 2009 earnings. Both companies' boards of directors have approved the deal, expected to close during the first quarter.
Mentor's chief executive, Josh Levine, will stay on as a member of Ethicon's global management board, Price said. Significant layoffs are not expected.
Analyst Dr. Sean Lavin of Lazard Capital Markets wrote that Johnson & Johnson "is purchasing Mentor at an optimal time, as the stock was down nearly 60% year to date."
Lavin doesn't expect other buyers to emerge, adding, "We cannot think of another company in as synergistic a position," given that J&J salespeople regularly call on general and plastic surgeons and dermatologists.
Mentor's key competitor in the breast implant market is Allergan Inc., the Irvine, Calif.-based maker of Botox. Mentor is developing its own antiwrinkle injection and dermal fillers to compete.
Most of Mentor's sales are in the U.S. and J&J, with a huge global sales operation, sees an opportunity to expand the business elsewhere, Price said.
The Mentor deal is the second buyout in as many weeks for cash-rich J&J, which on Nov. 24 bought biotech company Omrix Biopharmaceuticals Inc. for $438 million. The deal, expected to close late this month, will add products used to control bleeding during surgical procedures.
Gordon said he expects more acquisitions -- by J&J and also by pharmaceutical companies that have too weak a pipeline to support their overhead and need to either acquire products or merge with another large company and slash costs.
Overall, portions of the health care sector with cash-heavy balance sheets, such as big drugmakers, have been more open to acquisitions during the current recession.
AP Business Writer Damiam Troise in New York contributed to this report.
posted by Fab at
6:32 AM
2 Comments
